$PLX
Protalix BioTherapeutics, Inc.

2023 Q2 Form 10-Q Financial Statement

#000155837023008132 Filed on May 04, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $35.08M $9.588M $16.09M
YoY Change 300.72% -40.39% 42.09%
Cost Of Revenue $6.148M $3.085M $6.034M
YoY Change 50.43% -48.87% 26.63%
Gross Profit $28.93M $6.503M $10.05M
YoY Change 519.95% -35.3% 53.33%
Gross Profit Margin 82.47% 67.82% 62.49%
Selling, General & Admin $4.031M $3.115M $3.154M
YoY Change 54.39% -1.24% 0.51%
% of Gross Profit 13.94% 47.9% 31.38%
Research & Development $4.475M $5.847M $8.767M
YoY Change -40.96% -33.31% 23.1%
% of Gross Profit 15.47% 89.91% 87.23%
Depreciation & Amortization $290.0K $280.0K $270.0K
YoY Change 7.41% 3.7% -5.59%
% of Gross Profit 1.0% 4.31% 2.69%
Operating Expenses $8.506M $8.962M $11.92M
YoY Change -16.53% -24.82% 16.19%
Operating Profit $20.42M -$2.459M -$1.870M
YoY Change -469.68% 31.5% -49.53%
Interest Expense -$770.0K -$480.0K -$420.0K
YoY Change -505.26% 14.29% -76.92%
% of Operating Profit -3.77%
Other Income/Expense, Net -$774.0K -$477.0K -$416.0K
YoY Change -507.37% 14.66% -77.16%
Pretax Income $19.65M -$2.936M -$2.286M
YoY Change -468.34% 28.43% -58.28%
Income Tax $308.0K $195.0K
% Of Pretax Income 1.57%
Net Earnings $19.34M -$3.131M -$2.286M
YoY Change -462.56% 36.96% -58.25%
Net Earnings / Revenue 55.14% -32.66% -14.21%
Basic Earnings Per Share $0.29 -$0.05 -$0.05
Diluted Earnings Per Share $0.21 -$0.05 -$0.05
COMMON SHARES
Basic Shares Outstanding 65.41M 57.35M 45.84M
Diluted Shares Outstanding 83.20M 57.48M 45.84M

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $48.20M $33.00M $16.90M
YoY Change 285.6% 95.27% -14.65%
Cash & Equivalents $48.18M $33.04M $16.89M
Short-Term Investments
Other Short-Term Assets $1.708M $758.0K $1.123M
YoY Change -34.23% -32.5% -35.97%
Inventory $19.64M $20.30M $16.59M
Prepaid Expenses
Receivables $4.049M $1.304M $5.908M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $73.58M $55.40M $56.54M
YoY Change 48.04% -2.02% -37.66%
LONG-TERM ASSETS
Property, Plant & Equipment $4.637M $4.704M $4.894M
YoY Change -2.75% -3.88% 1.37%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $4.400M $1.300M $2.100M
YoY Change 214.29% -38.1% 16.67%
Total Long-Term Assets $14.84M $11.16M $11.85M
YoY Change 35.66% -5.83% -2.03%
TOTAL ASSETS
Total Short-Term Assets $73.58M $55.40M $56.54M
Total Long-Term Assets $14.84M $11.16M $11.85M
Total Assets $88.42M $66.56M $68.39M
YoY Change 45.81% -2.68% -33.47%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $18.55M $5.100M $7.900M
YoY Change 164.93% -35.44% 23.44%
Accrued Expenses $8.608M $1.100M $1.200M
YoY Change 682.55% -8.33% -14.29%
Deferred Revenue $11.79M $11.80M
YoY Change -0.09% 360.98%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $23.11M $31.52M $35.33M
YoY Change -25.36% -10.8% -56.31%
LONG-TERM LIABILITIES
Long-Term Debt $20.10M $28.30M $28.00M
YoY Change -28.21% 1.07%
Other Long-Term Liabilities $6.200M $5.800M $12.60M
YoY Change -46.09% -53.97% 48361.54%
Total Long-Term Liabilities $26.31M $34.04M $40.55M
YoY Change -33.52% -16.06% 445.93%
TOTAL LIABILITIES
Total Short-Term Liabilities $23.11M $31.52M $35.33M
Total Long-Term Liabilities $26.31M $34.04M $40.55M
Total Liabilities $49.42M $65.55M $75.88M
YoY Change -29.94% -13.61% -14.06%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $39.00M $1.008M -$7.486M
YoY Change
Total Liabilities & Shareholders Equity $88.42M $66.56M $68.39M
YoY Change 45.81% -2.68% -33.47%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income $19.34M -$3.131M -$2.286M
YoY Change -462.56% 36.96% -58.25%
Depreciation, Depletion And Amortization $290.0K $280.0K $270.0K
YoY Change 7.41% 3.7% -5.59%
Cash From Operating Activities $4.980M -$2.998M -$5.829M
YoY Change -167.66% -48.57% -40.73%
INVESTING ACTIVITIES
Capital Expenditures $200.0K $248.0K $229.0K
YoY Change 53.85% 8.3% -40.67%
Acquisitions
YoY Change
Other Investing Activities -$20.00K $20.00K $28.00K
YoY Change -104.08% -28.57% 0.0%
Cash From Investing Activities -$220.0K $4.732M -$16.26M
YoY Change -161.11% -129.11% -47.02%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 10.44M 14.23M
YoY Change 295.45%
NET CHANGE
Cash From Operating Activities 4.980M -2.998M -5.829M
Cash From Investing Activities -220.0K 4.732M -16.26M
Cash From Financing Activities 10.44M 14.23M
Net Change In Cash 15.20M 15.93M -22.10M
YoY Change -448.62% -172.07% -1511.95%
FREE CASH FLOW
Cash From Operating Activities $4.980M -$2.998M -$5.829M
Capital Expenditures $200.0K $248.0K $229.0K
Free Cash Flow $4.780M -$3.246M -$6.058M
YoY Change -163.82% -46.42% -40.72%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001006281
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-33357
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
PROTALIX BIOTHERAPEUTICS, INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
65-0643773
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
2 University Plaza
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 100
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Hackensack
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07601
CY2023Q1 dei City Area Code
CityAreaCode
201
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
696-9345
CY2023Q1 dei Security12b Title
Security12bTitle
Common stock, $0.001 par value
CY2023Q1 dei Trading Symbol
TradingSymbol
PLX
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NYSEAMER
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
65414917
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
33036000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17111000
CY2022Q4 plx Short Term Bank Deposits
ShortTermBankDeposits
5069000
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1304000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4586000
CY2023Q1 us-gaap Other Assets Current
OtherAssetsCurrent
758000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1310000
CY2023Q1 us-gaap Inventory Net
InventoryNet
20303000
CY2022Q4 us-gaap Inventory Net
InventoryNet
16804000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
55401000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
44880000
CY2023Q1 us-gaap Defined Benefit Plan Assets For Plan Benefits Noncurrent
DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
1252000
CY2022Q4 us-gaap Defined Benefit Plan Assets For Plan Benefits Noncurrent
DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
1267000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4704000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4553000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5202000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5087000
CY2023Q1 us-gaap Assets
Assets
66559000
CY2022Q4 us-gaap Assets
Assets
55787000
CY2023Q1 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
5105000
CY2022Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
5862000
CY2023Q1 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
13471000
CY2022Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
12271000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1149000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1118000
CY2023Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
11790000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
13178000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
31515000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
32429000
CY2023Q1 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
28267000
CY2022Q4 us-gaap Convertible Debt Noncurrent
ConvertibleDebtNoncurrent
28187000
CY2023Q1 us-gaap Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent
PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
1617000
CY2022Q4 us-gaap Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent
PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent
1642000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4152000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4169000
CY2023Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
34036000
CY2022Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
33998000
CY2023Q1 us-gaap Liabilities
Liabilities
65551000
CY2022Q4 us-gaap Liabilities
Liabilities
66427000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1008000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-10640000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
66559000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
55787000
CY2023Q1 us-gaap Revenues
Revenues
9588000
CY2022Q1 us-gaap Revenues
Revenues
16085000
CY2023Q1 us-gaap Cost Of Revenue
CostOfRevenue
3085000
CY2022Q1 us-gaap Cost Of Revenue
CostOfRevenue
6034000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5847000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8767000
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3115000
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3154000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2459000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1870000
CY2023Q1 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
649000
CY2022Q1 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
618000
CY2023Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
172000
CY2022Q1 us-gaap Other Nonoperating Income
OtherNonoperatingIncome
202000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-477000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-416000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2936000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2286000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
195000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-3131000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2286000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.05
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.05
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
57480009
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
57480009
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
45843563
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
45843563
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-6036000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
149000
CY2022Q1 plx Share Based Compensation Restricted Stock Awards Net Of Forfeitures
ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
687000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-2286000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-7486000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-10640000
CY2023Q1 plx Stock Issued During Period Value Sales Agreement
StockIssuedDuringPeriodValueSalesAgreement
14233000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
453000
CY2023Q1 plx Share Based Compensation Restricted Stock Awards Net Of Forfeitures
ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures
93000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-3131000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
1008000
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
144000000
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-3131000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-2286000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
546000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
836000
CY2023Q1 us-gaap Depreciation
Depreciation
280000
CY2022Q1 us-gaap Depreciation
Depreciation
270000
CY2023Q1 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
91000
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
198000
CY2023Q1 us-gaap Pension And Other Postretirement Benefit Expense
PensionAndOtherPostretirementBenefitExpense
19000
CY2022Q1 us-gaap Pension And Other Postretirement Benefit Expense
PensionAndOtherPostretirementBenefitExpense
75000
CY2023Q1 plx Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement
GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
-1000
CY2022Q1 plx Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement
GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
-10000
CY2023Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
80000
CY2022Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
75000
CY2023Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1388000
CY2022Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-2644000
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-3823000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2314000
CY2023Q1 plx Change In Operating Lease Right Of Use Assets
ChangeInOperatingLeaseRightOfUseAssets
-9000
CY2022Q1 plx Change In Operating Lease Right Of Use Assets
ChangeInOperatingLeaseRightOfUseAssets
2000
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3499000
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-1360000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
353000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1011000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2998000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5829000
CY2022Q1 plx Increase Decrease In Bank Deposits
IncreaseDecreaseInBankDeposits
16000000
CY2023Q1 plx Proceeds From Sale Of Short Term Deposits
ProceedsFromSaleOfShortTermDeposits
5000000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
248000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
229000
CY2023Q1 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
20000
CY2022Q1 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
28000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
4732000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-16257000
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
14233000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
14233000
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-42000
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-11000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
15925000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-22097000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17111000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
38985000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
33036000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16888000
CY2023Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
326000
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
67000
CY2023Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
312000
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
99000
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
1078000
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
1120000
CY2023Q1 plx Interest Received Net
InterestReceivedNet
78000
CY2022Q1 plx Interest Received Net
InterestReceivedNet
36000
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
36292208
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
33004217
CY2023Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
4308000
CY2022Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
3508000
CY2023Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
1533000
CY2022Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
2678000
CY2023Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
14462000
CY2022Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
10618000
CY2023Q1 us-gaap Inventory Net
InventoryNet
20303000
CY2022Q4 us-gaap Inventory Net
InventoryNet
16804000

Files In Submission

Name View Source Status
0001558370-23-008132-index-headers.html Edgar Link pending
0001558370-23-008132-index.html Edgar Link pending
0001558370-23-008132.txt Edgar Link pending
0001558370-23-008132-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
plx-20230331.xsd Edgar Link pending
plx-20230331x10q.htm Edgar Link pending
plx-20230331x10q005.jpg Edgar Link pending
plx-20230331x10q006.jpg Edgar Link pending
plx-20230331x10q007.jpg Edgar Link pending
plx-20230331xex31d1.htm Edgar Link pending
plx-20230331xex31d2.htm Edgar Link pending
plx-20230331xex32d1.htm Edgar Link pending
plx-20230331xex32d2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
plx-20230331_cal.xml Edgar Link unprocessable
plx-20230331_def.xml Edgar Link unprocessable
plx-20230331_lab.xml Edgar Link unprocessable
plx-20230331_pre.xml Edgar Link unprocessable
plx-20230331x10q_htm.xml Edgar Link completed